What it sells
The world's first AI-maximalist pharma company
Business model breakdown
Buyer: who owns the budget?
UnverifiedBusiness development or investment lead at biotech, pharma or VC.
Trigger: what makes them buy now?
Months of manual diligence on in-licensing candidates.
Workflow: what inputs become what output?
Asset Discovery Agent finds overlooked drug assets; 50+ in-silico models; PhD review; market insight, operational risk and probability-of-success models; final KOL roundtable go/no-go.
Economics: what it saves and how it charges
Subscription tiers plus per-report fees for drug-asset diligence.
Distribution: how it reaches customers
Self-serve agent trial and subscriptions plus demo/partnership contact form seeking pilot customers.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2025 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.